The FDA requested that manufacturers of GLP-1 receptor agonists remove information regarding risks of suicidal behavior and ideation from drug labels following a detailed review of existing data, the ...
Who controls the narrative, where the money is going, and why patients need to be at the centre of what comes next News ...
Medications for obesity may improve fertility, but there are many unknowns when it comes to using them during pregnancy.
A November 2025 Kaiser Family Foundation poll found that 1 in 8 U.S. adults have tried a GLP-1 medication for weight loss, diabetes or another condition. And we expect that number to rise now that one ...
Phenomix's MyPhenome test continues to demonstrate predictive accuracy in identifying which patients are most likely to respond to GLP-1 therapies such as semaglutide. Studies presented at Obesity ...
Soaring in popularity, GLP-1 medications—from weekly injections to newly available pills—are rapidly reshaping how Americans ...
A new umbrella review reveals how GLP-1 therapies shape cardiovascular, renal, and metabolic outcomes in type 2 diabetes while highlighting drug-specific advantages and the need to manage ...
For now, GLP-1 drugs remain a powerful tool for diabetes and obesity, with the potential to become much more. As research ...
Dec 23 (Reuters) - The U.S. Centers for Medicare and Medicaid Services on Tuesday unveiled a voluntary program to cover GLP-1 drugs for weight-loss and diabetes under Medicaid and Medicare Part D ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results